{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:54:02Z","timestamp":1789912442519,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32270566"],"award-info":[{"award-number":["32270566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shaanxi Province Innovation Capability Support Plan","award":["2025JC-GXPT-043"],"award-info":[{"award-number":["2025JC-GXPT-043"]}]},{"name":"Laboratory Animal Foundation Program of Military","award":["SYDW_KY 2021-14"],"award-info":[{"award-number":["SYDW_KY 2021-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04225-7","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:23:55Z","timestamp":1763443435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Construction and application of a humanized mouse model for prostate cancer in immunotherapy"],"prefix":"10.1007","volume":"74","author":[{"given":"Wenwen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"4225_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"4225_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M, Coussens L, Gabrilovich D, Ostrand-Rosenberg S, Hedrick C, Vonderheide R, Pittet M, Jain R, Zou W, Howcroft T, Woodhouse E, Weinberg R, Krummel M (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550","journal-title":"Nat Med"},{"key":"4225_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 17:725\u2013741","journal-title":"Nat Rev Clin Oncol"},{"key":"4225_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccell.2022.04.007","volume":"40","author":"L Pala","year":"2022","unstructured":"Pala L, De Pas T, Conforti F (2022) Boosting anticancer immunotherapy through androgen receptor blockade. Cancer Cell 40:455\u2013457","journal-title":"Cancer Cell"},{"key":"4225_CR5","first-page":"7","volume":"72","author":"R Siegel","year":"2022","unstructured":"Siegel R, Miller K, Fuchs H, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4225_CR6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford E (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180\u20131192","journal-title":"Int J Clin Pract"},{"key":"4225_CR7","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn P, Thompson T (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501\u20135511","journal-title":"Oncogene"},{"key":"4225_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"M Teo","year":"2019","unstructured":"Teo M, Rathkopf D, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479\u2013499","journal-title":"Annu Rev Med"},{"key":"4225_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd3220","volume":"9","author":"C Higano","year":"2010","unstructured":"Higano C, Small E, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff P (2010) Sipuleucel-T. Nat Rev Drug Discov 9:513\u2013514","journal-title":"Nat Rev Drug Discov"},{"key":"4225_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081778","author":"P Xu","year":"2022","unstructured":"Xu P, Wasielewski L, Yang J, Cai D, Evans C, Murphy W, Liu C (2022) The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10081778","journal-title":"Biomedicines"},{"key":"4225_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-030-73119-9_16","volume":"1329","author":"S Nagireddy","year":"2021","unstructured":"Nagireddy S, Qureshi R, Best J, Frech F, Shah K, Soni Y, Kuchakulla M, Narasimman M, Arora H (2021) Current treatment modalities targeting tumor microenvironment in castration-resistant prostate cancer. Adv Exp Med Biol 1329:295\u2013323","journal-title":"Adv Exp Med Biol"},{"key":"4225_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","volume":"14","author":"V Murillo-Garz\u00f3n","year":"2017","unstructured":"Murillo-Garz\u00f3n V, Kypta R (2017) WNT signalling in prostate cancer. Nat Rev Urol 14:683\u2013696","journal-title":"Nat Rev Urol"},{"key":"4225_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu E, Aslan M, Rice M, Nguyen H, Brooks J, Corey E, Paulmurugan R, Stoyanova T (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81:1583\u20131594","journal-title":"Cancer Res"},{"key":"4225_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2018.07.001","volume":"39","author":"P De La Rochere","year":"2018","unstructured":"De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu S, Piaggio E (2018) Humanized mice for the study of immuno-oncology. Trends Immunol 39:748\u2013763","journal-title":"Trends Immunol"},{"key":"4225_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673199","volume":"11","author":"W Guo","year":"2021","unstructured":"Guo W, Zhang C, Qiao T, Zhao J, Shi C (2021) Strategies for the construction of mouse models with humanized immune system and evaluation of tumor immune checkpoint inhibitor therapy. Front Oncol 11:673199","journal-title":"Front Oncol"},{"key":"4225_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","volume":"67","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Shuen T, Toh T, Chan X, Liu M, Tan S, Fan Y, Yang H, Lyer S, Bonney G, Loh E, Chang K, Tan T, Zhai W, Chan J, Chow E, Chee C, Lee G, Dan Y, Chow P, Toh H, Lim S, Chen Q (2018) Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 67:1845\u20131854","journal-title":"Gut"},{"key":"4225_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00335-019-09796-2","volume":"30","author":"L Shultz","year":"2019","unstructured":"Shultz L, Keck J, Burzenski L, Jangalwe S, Vaidya S, Greiner D, Brehm M (2019) Humanized mouse models of immunological diseases and precision medicine. Mamm genome off j Int Mamm Genome Soc 30:123\u2013142","journal-title":"Mamm genome off j Int Mamm Genome Soc"},{"key":"4225_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2018.11.035","volume":"127","author":"K Pyo","year":"2019","unstructured":"Pyo K, Kim J, Lee J, Kim S, Cho J, Lim S, Cho B (2019) Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Lung cancer (Amsterdam, Netherlands) 127:112\u2013121","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"4225_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2326-6066.CIR-18-0874","volume":"7","author":"I Meraz","year":"2019","unstructured":"Meraz I, Majidi M, Meng F, Shao R, Ha M, Neri S, Fang B, Lin S, Tinkey P, Shpall E, Morris J, Roth J (2019) An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol Res 7:1267\u20131279","journal-title":"Cancer Immunol Res"},{"key":"4225_CR20","first-page":"4568","volume":"10","author":"L Yin","year":"2020","unstructured":"Yin L, Wang X, Chen D, Liu X, Wang X (2020) Humanized mouse model: a review on preclinical applications for cancer immunotherapy. Am J Cancer Res 10:4568\u20134584","journal-title":"Am J Cancer Res"},{"issue":"22","key":"4225_CR21","doi-asserted-by":"publisher","first-page":"2105810","DOI":"10.1002\/advs.202105810","volume":"9","author":"W Wenwen","year":"2022","unstructured":"Wenwen W, Tinggan Y, Lili M, Yanjing Z, Jinxia B, Xiaofang Z, Yan Z, Yali Z, Yani Z, Shuai Y, Xinyao Q, Siyun S, Rui W, Tong W, Hongyang W, Dong G, Peng W, Lei C (2022) Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci (Weinh) 9(22):2105810","journal-title":"Adv Sci (Weinh)"},{"key":"4225_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.21037\/tau.2019.08.31","volume":"8","author":"C Shi","year":"2019","unstructured":"Shi C, Chen X, Tan D (2019) Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity. Transl Androl Urol 8:519\u2013528","journal-title":"Transl Androl Urol"},{"key":"4225_CR23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","volume":"21","author":"M Galsky","year":"2010","unstructured":"Galsky M, Vogelzang N (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135\u20132144","journal-title":"Ann Oncol"},{"key":"4225_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cpph.77","volume":"89","author":"B Verma","year":"2020","unstructured":"Verma B, Wesa A (2020) Establishment of humanized mice from peripheral blood mononuclear cells or cord blood CD34+ hematopoietic stem cells for immune-oncology studies evaluating new therapeutic agents. Curr Protoc Pharmacol 89:e77","journal-title":"Curr Protoc Pharmacol"},{"key":"4225_CR25","doi-asserted-by":"publisher","first-page":"673199","DOI":"10.3389\/fonc.2021.673199","volume":"11","author":"G Wenwen","year":"2021","unstructured":"Wenwen G, Caiqin Z, Tianyun Q, Jumei Z, Changhong S (2021) Strategies for the construction of mouse models with humanized immune system and evaluation of tumor immune checkpoint inhibitor therapy. Front Oncol 11:673199","journal-title":"Front Oncol"},{"issue":"3","key":"4225_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, Shultz LD, Brehm MA (2023) Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol 20(3):192\u2013206","journal-title":"Nat Rev Clin Oncol"},{"key":"4225_CR27","doi-asserted-by":"publisher","first-page":"104816","DOI":"10.1016\/j.cellimm.2024.104816","volume":"399","author":"A Giatromanolaki","year":"2024","unstructured":"Giatromanolaki A, Michos GD, Xanthopoulou E, Koukourakis MI (2024) HLA-class-I expression loss, tumor microenvironment and breast cancer prognosis. Cell Immunol 399:104816","journal-title":"Cell Immunol"},{"key":"4225_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li T, Qiao T (2022) Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy. Semin Cancer Biol 86:117\u2013125","journal-title":"Semin Cancer Biol"},{"key":"4225_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.semcancer.2020.01.001","volume":"65","author":"K Olino","year":"2020","unstructured":"Olino K, Park T, Ahuja N (2020) Exposing hidden targets: combining epigenetic and immunotherapy to overcome cancer resistance. Semin Cancer Biol 65:114\u2013122","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"4225_CR30","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"M Zehua","year":"2022","unstructured":"Zehua M, Weiwei Z, Baijun D, Zhixiang X, Yiyi J, Ruopeng S, Kai S, Jiahua P, Qi W, Wei X (2022) Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics 12(11):4965","journal-title":"Theranostics"},{"key":"4225_CR31","doi-asserted-by":"crossref","unstructured":"Animesh K, Dolly J, Sandeep K, Kajal R, Sanjay P, Kajal R, Raunak K, Somesh K J, Nihal M, Prabhu Srinivas Y, Nishant P, Devashish M, Harsh S, Debanjan B, Manas K P, Ravi Datta S, Aasheesh S, Usha A, Arnab M, Sagar S, Veena S P, Avinash B, Ujjaini D (2023) A localized hydrogel-mediated chemotherapy causes immunogenic cell death via activation of ceramide-mediated unfolded protein response. Sci Adv 9(26): 2746","DOI":"10.1126\/sciadv.adf2746"},{"key":"4225_CR32","doi-asserted-by":"crossref","unstructured":"Karim F, Pablo GM, Daniel C, Jose N M, Arash RK, David S, Juan C VL, H\u00e9ctor M SL, Andrew J A, Lisa H, Diogo A B, Neha P A, Jia L, Keziban U-K, Margitta R, Fred S, Daniel P P, Russell K P (2021) Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial Eur J Cancer 160: 61\u201371","DOI":"10.1016\/j.ejca.2021.09.043"},{"key":"4225_CR33","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Sun Z (2021) Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11:5365\u20135386","journal-title":"Theranostics"},{"key":"4225_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","volume":"83","author":"E Yu","year":"2023","unstructured":"Yu E, Piulats J, Gravis G, Fong P, Todenh\u00f6fer T, Laguerre B, Arranz J, Oudard S, Massard C, Heinzelbecker J, Nordquist L, Carles J, Kolinsky M, Augustin M, Gurney H, Tafreshi A, Li X, Qiu P, Poehlein C, Schloss C, de Bono J (2023) Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: Long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study. Eur Urol 83:15\u201326","journal-title":"Eur Urol"},{"key":"4225_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004761","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Retz M, Petrylak D, Goh J, Perez-Gracia J, Lacombe L, Zsch\u00e4bitz S, Burotto M, Mahammedi H, Gravis G, Bastos D, McCune S, V\u00e1zquez Lim\u00f3n J, Kwan E, Castellano D, Fl\u00e9chon A, Saad F, Grimm M, Shaffer D, Armstrong A, Bhagavatheeswaran P, Amin N, \u00dcnsal-Ka\u00e7maz K, Wang X, Li J, Loehr A, Pachynski R (2022) Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-004761","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:36Z","timestamp":1764600336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4225"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04225-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the participants and the patient with PCa, respectively.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of FMMU (Protocol No. 20220705). Fresh peripheral blood and PCa tumor tissue were collected from the Xi\u2019jing Hospital in Xi'an and approved by the Medical Ethics Committee (KY20203128-1).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"377"}}